JP2005532050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005532050A5 JP2005532050A5 JP2004516175A JP2004516175A JP2005532050A5 JP 2005532050 A5 JP2005532050 A5 JP 2005532050A5 JP 2004516175 A JP2004516175 A JP 2004516175A JP 2004516175 A JP2004516175 A JP 2004516175A JP 2005532050 A5 JP2005532050 A5 JP 2005532050A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- cell
- carcinoma
- raag10
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 39
- 210000004027 cell Anatomy 0.000 claims 36
- 201000011510 cancer Diseases 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 206010024612 Lipoma Diseases 0.000 claims 11
- 230000001394 metastastic effect Effects 0.000 claims 11
- 206010061289 metastatic neoplasm Diseases 0.000 claims 11
- 206010039491 Sarcoma Diseases 0.000 claims 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims 8
- 208000005243 Chondrosarcoma Diseases 0.000 claims 8
- 206010009944 Colon cancer Diseases 0.000 claims 8
- 108060003951 Immunoglobulin Proteins 0.000 claims 8
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 8
- 206010038389 Renal cancer Diseases 0.000 claims 8
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- 102000018358 immunoglobulin Human genes 0.000 claims 8
- 201000010982 kidney cancer Diseases 0.000 claims 8
- 150000007523 nucleic acids Chemical group 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 8
- 208000008732 thymoma Diseases 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 201000001441 melanoma Diseases 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 208000030507 AIDS Diseases 0.000 claims 4
- 208000001783 Adamantinoma Diseases 0.000 claims 4
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 claims 4
- 208000008884 Aneurysmal Bone Cysts Diseases 0.000 claims 4
- 206010004593 Bile duct cancer Diseases 0.000 claims 4
- 208000019838 Blood disease Diseases 0.000 claims 4
- 206010005949 Bone cancer Diseases 0.000 claims 4
- 208000018084 Bone neoplasm Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 208000001843 Carotid Body Tumor Diseases 0.000 claims 4
- 208000037211 Carotid body tumour Diseases 0.000 claims 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims 4
- 201000009047 Chordoma Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 208000013558 Developmental Bone disease Diseases 0.000 claims 4
- 206010014733 Endometrial cancer Diseases 0.000 claims 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 4
- 206010014967 Ependymoma Diseases 0.000 claims 4
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 4
- 208000021309 Germ cell tumor Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 208000000172 Medulloblastoma Diseases 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 4
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 4
- 206010029260 Neuroblastoma Diseases 0.000 claims 4
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 4
- 206010033963 Parathyroid tumour Diseases 0.000 claims 4
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 206010072610 Skeletal dysplasia Diseases 0.000 claims 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 4
- 206010057644 Testis cancer Diseases 0.000 claims 4
- 201000009365 Thymic carcinoma Diseases 0.000 claims 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 4
- 208000008383 Wilms tumor Diseases 0.000 claims 4
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims 4
- 210000000988 bone and bone Anatomy 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 4
- 201000010881 cervical cancer Diseases 0.000 claims 4
- 208000019065 cervical carcinoma Diseases 0.000 claims 4
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 4
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 230000002124 endocrine Effects 0.000 claims 4
- 201000003914 endometrial carcinoma Diseases 0.000 claims 4
- 230000003352 fibrogenic effect Effects 0.000 claims 4
- 210000000232 gallbladder Anatomy 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 201000010536 head and neck cancer Diseases 0.000 claims 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims 4
- 208000014951 hematologic disease Diseases 0.000 claims 4
- 208000018706 hematopoietic system disease Diseases 0.000 claims 4
- 208000006359 hepatoblastoma Diseases 0.000 claims 4
- 210000004408 hybridoma Anatomy 0.000 claims 4
- 208000022013 kidney Wilms tumor Diseases 0.000 claims 4
- 201000010260 leiomyoma Diseases 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 206010024627 liposarcoma Diseases 0.000 claims 4
- 201000007270 liver cancer Diseases 0.000 claims 4
- 208000014018 liver neoplasm Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 230000003211 malignant effect Effects 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 206010027191 meningioma Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 201000008026 nephroblastoma Diseases 0.000 claims 4
- 208000007538 neurilemmoma Diseases 0.000 claims 4
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 4
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 4
- 201000008968 osteosarcoma Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 230000002093 peripheral effect Effects 0.000 claims 4
- 208000028591 pheochromocytoma Diseases 0.000 claims 4
- 208000010916 pituitary tumor Diseases 0.000 claims 4
- 206010039667 schwannoma Diseases 0.000 claims 4
- 201000000849 skin cancer Diseases 0.000 claims 4
- 201000011096 spinal cancer Diseases 0.000 claims 4
- 208000014618 spinal cord cancer Diseases 0.000 claims 4
- 210000004500 stellate cell Anatomy 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 206010042863 synovial sarcoma Diseases 0.000 claims 4
- 201000003120 testicular cancer Diseases 0.000 claims 4
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 4
- 208000017997 tumor of parathyroid gland Diseases 0.000 claims 4
- 206010046766 uterine cancer Diseases 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 3
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 3
- 208000000035 Osteochondroma Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 201000010175 gallbladder cancer Diseases 0.000 claims 3
- 208000003884 gestational trophoblastic disease Diseases 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 206010020718 hyperplasia Diseases 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 201000002529 islet cell tumor Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims 3
- 201000010279 papillary renal cell carcinoma Diseases 0.000 claims 3
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000002267 posterior uveal melanoma Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 210000001745 uvea Anatomy 0.000 claims 2
- 201000005262 Chondroma Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010018498 Goitre Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 201000008822 gestational choriocarcinoma Diseases 0.000 claims 1
- 201000003872 goiter Diseases 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 210000002445 nipple Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003741 urothelium Anatomy 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39020302P | 2002-06-19 | 2002-06-19 | |
| PCT/US2003/019819 WO2004001381A2 (en) | 2002-06-19 | 2003-06-19 | Novel raag10 cell surface target and a family of antibodies recognizing that target |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010000787A Division JP2010110329A (ja) | 2002-06-19 | 2010-01-05 | 新規のｒａａｇ１０細胞表面標的および当該標的を認識する抗体ファミリー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005532050A JP2005532050A (ja) | 2005-10-27 |
| JP2005532050A5 true JP2005532050A5 (https=) | 2006-08-03 |
| JP4488512B2 JP4488512B2 (ja) | 2010-06-23 |
Family
ID=30000526
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004516175A Expired - Lifetime JP4488512B2 (ja) | 2002-06-19 | 2003-06-19 | 新規のｒａａｇ１０細胞表面標的および当該標的を認識する抗体ファミリー |
| JP2010000787A Pending JP2010110329A (ja) | 2002-06-19 | 2010-01-05 | 新規のｒａａｇ１０細胞表面標的および当該標的を認識する抗体ファミリー |
| JP2011012411A Expired - Lifetime JP5372973B2 (ja) | 2002-06-19 | 2011-01-24 | 新規のｒａａｇ１０細胞表面標的および当該標的を認識する抗体ファミリー |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010000787A Pending JP2010110329A (ja) | 2002-06-19 | 2010-01-05 | 新規のｒａａｇ１０細胞表面標的および当該標的を認識する抗体ファミリー |
| JP2011012411A Expired - Lifetime JP5372973B2 (ja) | 2002-06-19 | 2011-01-24 | 新規のｒａａｇ１０細胞表面標的および当該標的を認識する抗体ファミリー |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US7527969B2 (https=) |
| EP (2) | EP1565489B1 (https=) |
| JP (3) | JP4488512B2 (https=) |
| AT (1) | ATE488530T1 (https=) |
| AU (1) | AU2003243749B2 (https=) |
| CA (1) | CA2490399C (https=) |
| DE (1) | DE60335022D1 (https=) |
| DK (1) | DK1565489T3 (https=) |
| ES (1) | ES2356444T3 (https=) |
| MX (1) | MXPA04012664A (https=) |
| PT (1) | PT1565489E (https=) |
| WO (1) | WO2004001381A2 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04012664A (es) | 2002-06-19 | 2005-08-15 | Raven Biotechnologies Inc | Objetivo de superficie celular raag10 novedoso y una familia de anticuerpos que reconocen ese objetivo. |
| ATE548389T1 (de) | 2004-08-03 | 2012-03-15 | Innate Pharma | Therapeutische und diagnostische verfahren und zusammensetzungen zum targeting von 4ig-b7-h3 und dem entsprechenden nk-zellen-rezeptor |
| JP2009221164A (ja) | 2008-03-17 | 2009-10-01 | Nitto Denko Corp | 肺線維症処置剤 |
| US20120269886A1 (en) | 2004-12-22 | 2012-10-25 | Nitto Denko Corporation | Therapeutic agent for pulmonary fibrosis |
| EP1846032A4 (en) * | 2005-01-31 | 2009-01-28 | Raven Biotechnologies Inc | LUCA2 AND THEREO BINDING ANTIBODIES |
| AU2006210589B2 (en) | 2005-02-02 | 2011-12-08 | Macrogenics West, Inc. | ADAM-9 modulators |
| US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US9572886B2 (en) | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
| US7718774B2 (en) * | 2006-11-08 | 2010-05-18 | Macrogenics, Inc. | TES7 and antibodies that bind thereto |
| WO2008057632A1 (en) * | 2006-11-09 | 2008-05-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Differential gene expression in physiological and pathological angiogenesis |
| KR101523698B1 (ko) | 2007-01-22 | 2015-05-29 | 마크로제닉스 웨스트 인코퍼레이티드 | 사람 암 줄기세포 |
| TWI407971B (zh) | 2007-03-30 | 2013-09-11 | 日東電工股份有限公司 | Cancer cells and tumor-related fibroblasts |
| AU2009258063B2 (en) | 2007-06-21 | 2014-09-25 | Macrogenics, Inc. | BCR-complex-specific antibodies and methods of using same |
| EP2376109B1 (en) | 2008-12-19 | 2019-01-23 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| ES2666152T3 (es) | 2009-08-13 | 2018-05-03 | The Johns Hopkins University | Métodos de modulación de la función inmunitaria con anticuerpos anti-B7-H7CR |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス，インコーポレーテッド | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| EP2601216B1 (en) | 2010-08-02 | 2018-01-03 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| JP5950428B2 (ja) | 2010-08-05 | 2016-07-13 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
| US8642951B2 (en) | 2011-05-04 | 2014-02-04 | Agilent Technologies, Inc. | Device, system, and method for reflecting ions |
| CA2836873C (en) | 2011-05-21 | 2019-10-22 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use for extending serum half-life |
| RU2639459C2 (ru) | 2011-06-21 | 2017-12-21 | Нитто Денко Корпорейшн | Апоптоз-индуцирующее средство |
| JP6340162B2 (ja) | 2012-12-20 | 2018-06-06 | 日東電工株式会社 | アポトーシス誘導剤 |
| JP6076076B2 (ja) | 2012-12-21 | 2017-02-08 | 日東電工株式会社 | 組織再生促進剤 |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| KR20160135190A (ko) | 2014-02-14 | 2016-11-25 | 앤드류 에스. 카이 | 혈관형성 암의 치료를 위한 개선된 방법 |
| CA2944417A1 (en) | 2014-04-02 | 2015-10-08 | Nitto Denko Corporation | A targeting molecule and a use thereof |
| EP3129425B1 (en) | 2014-04-07 | 2019-04-10 | Nitto Denko Corporation | Polymer-based hydrotropes for hydrophobic drug delivery |
| JP6727765B2 (ja) | 2014-06-17 | 2020-07-22 | 日東電工株式会社 | アポトーシス誘導剤 |
| CN108136010A (zh) | 2015-10-08 | 2018-06-08 | 宏观基因有限公司 | 用于治疗癌症的联合疗法 |
| US10954301B2 (en) | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| TWI781098B (zh) | 2016-04-15 | 2022-10-21 | 美商宏觀基因股份有限公司 | 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法 |
| MX2018014950A (es) | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| EP3458479B1 (en) * | 2016-06-08 | 2020-11-04 | AbbVie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| IL268836B2 (en) | 2017-02-24 | 2024-04-01 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| JP7264831B2 (ja) * | 2017-06-15 | 2023-04-25 | ディベロップメント センター フォー バイオテクノロジー | 抗ｇｌｏｂｏ ｈ抗体を含有する抗体－薬物コンジュゲートおよびその使用 |
| SG11202005557TA (en) | 2017-12-12 | 2020-07-29 | Macrogenics Inc | Bispecific cd 16-binding molecules and their use in the treatment of disease |
| SG11202007572VA (en) | 2018-02-15 | 2020-09-29 | Macrogenics Inc | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
| EP4106813A4 (en) | 2020-02-21 | 2024-03-27 | MacroGenics, Inc. | CD137 BINDING MOLECULES AND THEIR USES |
| JP2024511277A (ja) | 2021-02-19 | 2024-03-13 | メビオン・メディカル・システムズ・インコーポレーテッド | 粒子線治療システムのためのガントリー |
| MX2024000406A (es) | 2021-07-19 | 2024-04-18 | Regeneron Pharma | Combinacion de inhibidores de puntos de control y un virus oncolitico para el tratamiento del cancer. |
| US20250152643A1 (en) | 2022-02-17 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Combinations of checkpoint inhibitors and oncolytic virus for treating cancer |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5552391A (en) * | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) * | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| AU669124B2 (en) * | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US6001359A (en) * | 1993-06-29 | 1999-12-14 | Eli Lilly And Company | Diagnosis of colon carcinoma using monoclonal antibodies to human influx peptide transporter |
| US5532159A (en) | 1994-04-01 | 1996-07-02 | The Ohio State University | Monoclonal antibody to canine placental oncofetal protein for detecting cancer |
| US6265150B1 (en) * | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| JP3868740B2 (ja) | 1998-03-10 | 2007-01-17 | ジェネンテック・インコーポレーテッド | 新規なポリペプチド及びそれをコードする核酸 |
| AU4640600A (en) | 1999-05-11 | 2000-11-21 | Eli Lilly And Company | Amyloid precursor protein protease and related nucleic acid compounds |
| EP1514933A1 (en) | 1999-07-08 | 2005-03-16 | Research Association for Biotechnology | Secretory protein or membrane protein |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| WO2001014577A1 (en) | 1999-08-24 | 2001-03-01 | Smithkline Beecham Corporation | Molecular cloning of a galanin like 7tm receptor (axor40) |
| US6429303B1 (en) | 1999-09-03 | 2002-08-06 | Curagen Corporation | Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same |
| CA2389916A1 (en) * | 1999-09-03 | 2001-03-15 | Human Genome Sciences, Inc. | B7-like polynucleotides, polypeptides, and antibodies |
| US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
| US6416999B1 (en) * | 2000-04-07 | 2002-07-09 | Raven Biotechnologies, Inc. | Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof |
| US6436704B1 (en) * | 2000-04-10 | 2002-08-20 | Raven Biotechnologies, Inc. | Human pancreatic epithelial progenitor cells and methods of isolation and use thereof |
| US6987024B1 (en) | 2000-04-10 | 2006-01-17 | Raven Biotechnologies, Inc. | Human ovarian mesothelial cells and methods of isolation and uses thereof |
| US20060154313A1 (en) * | 2000-04-13 | 2006-07-13 | Immunex Corporation | Human B7 polypeptide B7-H3A |
| AU2001264747A1 (en) | 2000-05-22 | 2001-12-03 | Idec Pharmaceuticals Corporation | Identification of unique binding interactions between certain antibodies and thehuman b7.1 and b7.2 co-stimulatory antigens |
| CA2412377A1 (en) * | 2000-06-06 | 2001-12-13 | Bristol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| EP1892251A3 (en) | 2000-06-06 | 2008-12-31 | Brystol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| US6635750B1 (en) | 2000-07-20 | 2003-10-21 | Millennium Pharmaceuticals, Inc. | B7-H2 nucleic acids, members of the B7 family |
| US6891030B2 (en) * | 2000-07-27 | 2005-05-10 | Mayo Foundation For Medical Education And Research | T-cell immunoregulatory molecule |
| AU2001286205A1 (en) * | 2000-09-12 | 2002-03-26 | Kirin Beer Kabushiki Kaisha | Novel dendritic cell wall membrane and use thereof |
| US20030134283A1 (en) * | 2000-10-03 | 2003-07-17 | Peterson David P. | Genes regulated in dendritic cell differentiation |
| EP1399187A4 (en) | 2000-10-18 | 2005-09-21 | Sloan Kettering Inst Cancer | APPLICATIONS OF MONOCLONAL ANTIBODY 8H9 |
| EP1401999A4 (en) * | 2001-05-25 | 2005-09-14 | Amgen Inc | PROTEIN-2 MOLECULES ASSOCIATED WITH B7 AND USE THEREOF |
| US20070015144A9 (en) * | 2001-05-25 | 2007-01-18 | Genset, S.A. | Human cDNAs and proteins and uses thereof |
| EP1390497A2 (en) * | 2001-05-25 | 2004-02-25 | Genset | Human cdnas and proteins and uses thereof |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| WO2003014293A2 (en) * | 2001-08-02 | 2003-02-20 | Eli Lilly And Company | Novel polypeptide analogs and fusions and their methods of use |
| CA2475356A1 (en) | 2002-02-12 | 2003-08-21 | Raven Biotechnologies, Inc. | Human fetal bladder-derived epithelial cells |
| US20040162236A1 (en) * | 2002-04-01 | 2004-08-19 | John Alsobrook | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| MXPA04012664A (es) * | 2002-06-19 | 2005-08-15 | Raven Biotechnologies Inc | Objetivo de superficie celular raag10 novedoso y una familia de anticuerpos que reconocen ese objetivo. |
| WO2004001004A2 (en) * | 2002-06-21 | 2003-12-31 | Johns Hopkins University School Of Medicine | Membrane associated tumor endothelium markers |
-
2003
- 2003-06-19 MX MXPA04012664A patent/MXPA04012664A/es active IP Right Grant
- 2003-06-19 AU AU2003243749A patent/AU2003243749B2/en not_active Expired
- 2003-06-19 WO PCT/US2003/019819 patent/WO2004001381A2/en not_active Ceased
- 2003-06-19 JP JP2004516175A patent/JP4488512B2/ja not_active Expired - Lifetime
- 2003-06-19 AT AT03761281T patent/ATE488530T1/de active
- 2003-06-19 CA CA2490399A patent/CA2490399C/en not_active Expired - Lifetime
- 2003-06-19 ES ES03761281T patent/ES2356444T3/es not_active Expired - Lifetime
- 2003-06-19 EP EP03761281A patent/EP1565489B1/en not_active Expired - Lifetime
- 2003-06-19 PT PT03761281T patent/PT1565489E/pt unknown
- 2003-06-19 DE DE60335022T patent/DE60335022D1/de not_active Expired - Lifetime
- 2003-06-19 US US10/600,802 patent/US7527969B2/en not_active Expired - Lifetime
- 2003-06-19 EP EP10180500A patent/EP2277917A3/en not_active Withdrawn
- 2003-06-19 DK DK03761281.9T patent/DK1565489T3/da active
-
2009
- 2009-03-27 US US12/413,483 patent/US8779098B2/en not_active Expired - Lifetime
-
2010
- 2010-01-05 JP JP2010000787A patent/JP2010110329A/ja active Pending
-
2011
- 2011-01-24 JP JP2011012411A patent/JP5372973B2/ja not_active Expired - Lifetime
-
2014
- 2014-06-03 US US14/294,935 patent/US9574007B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005532050A5 (https=) | ||
| JP2010508847A5 (https=) | ||
| JP2008529494A5 (https=) | ||
| JP2010110329A5 (https=) | ||
| JP2008532488A5 (https=) | ||
| TWI779386B (zh) | 抗trop2抗體及其生產方法、及抗trop2抗體-藥物結合物 | |
| JP2011130770A5 (https=) | ||
| KR101916553B1 (ko) | 항-her2 항체-약물 접합체 | |
| EP2552966B1 (en) | Antibodies against csf-1r | |
| CN102459346B (zh) | 制造异源多聚体分子的方法 | |
| AU773568B2 (en) | Antobody to human gastrointestinal epithelial tumor antigen related to alpha 6 beta 4 integrin | |
| JP2022502371A (ja) | Ｄｌｌ３結合タンパク質および使用方法 | |
| CN102939306B (zh) | 用于治疗癌症的人源化抗cxcr4抗体 | |
| WO2021228141A1 (zh) | 抗体药物缀合物及其制备方法和用途 | |
| JP2005505256A5 (https=) | ||
| JP2008099684A (ja) | ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用 | |
| JP2017500028A (ja) | 新規の抗ｄｐｅｐ３抗体および使用方法 | |
| JP2010535713A5 (https=) | ||
| JP2005524399A5 (https=) | ||
| WO2007114496A1 (ja) | 新規抗ｃｄ９８抗体 | |
| CN102027014A (zh) | 用于治疗癌症的新抗体 | |
| JP2008526256A5 (https=) | ||
| CN117440973A (zh) | 与ror1结合的抗原结合蛋白 | |
| JP2008508858A5 (https=) | ||
| JP2008538173A5 (https=) |